Lusvarghi Sabrina, Robey Robert W, Gottesman Michael M, Ambudkar Suresh V
Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Dr., Bethesda, MD, 20892, USA.
F1000Res. 2020 Jan 13;9. doi: 10.12688/f1000research.21295.1. eCollection 2020.
P-glycoprotein, ABCG2, and MRP1 are members of the ATP-binding cassette (ABC) transporter superfamily that utilize energy from ATP-binding and hydrolysis to efflux a broad range of chemically dissimilar substrates including anticancer drugs. As a consequence, they play an important role in the pharmacokinetics and bioavailability of many drugs; in particular, their role in multidrug resistance in cancer cells as well as at the blood-brain barrier has been the subject of studies for decades. However, the atomic structures of these transporters in the presence of substrates or modulators and at different stages of the ATP-hydrolysis cycle have only recently been resolved by using cryo-electron microscopy. In addition, new animal models have shed new light on our understanding of the role of these transporters at the blood-brain barrier. This new information should open doors for the design of novel chemotherapeutics and treatments to bypass recognition by ABC drug pumps to overcome clinical drug resistance. In this review, we discuss the most recent advances in our understanding of ligand interactions and mechanistic aspects of drug transport based on atomic structures of these transporters as well as the development of new models to study their role in clinical drug resistance in cancer.
P-糖蛋白、ABCG2和多药耐药相关蛋白1(MRP1)是ATP结合盒(ABC)转运蛋白超家族的成员,它们利用ATP结合和水解产生的能量,外排包括抗癌药物在内的多种化学性质不同的底物。因此,它们在许多药物的药代动力学和生物利用度中发挥着重要作用;特别是,它们在癌细胞多药耐药以及血脑屏障中的作用,数十年来一直是研究的主题。然而,直到最近,通过冷冻电子显微镜才解析出这些转运蛋白在存在底物或调节剂以及ATP水解循环不同阶段的原子结构。此外,新的动物模型为我们理解这些转运蛋白在血脑屏障中的作用提供了新的视角。这些新信息应为设计新型化疗药物和治疗方法打开大门,以绕过ABC药物泵的识别,克服临床耐药性。在这篇综述中,我们基于这些转运蛋白的原子结构,讨论了我们对配体相互作用和药物转运机制方面理解的最新进展,以及研究它们在癌症临床耐药中作用的新模型的开发。